Onyx Pharmaceuticals Inc (ONXX.OQ)

ONXX.OQ on NASDAQ Stock Exchange Global Select Market

134.40USD
1 Aug 2013
Price Change (% chg)

$3.10 (+2.36%)
Prev Close
$131.30
Open
$131.48
Day's High
$135.16
Day's Low
$131.48
Volume
489,722
Avg. Vol
449,242
52-wk High
$136.86
52-wk Low
$66.40

ONXX.OQ

Chart for ONXX.OQ

About

Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib... (more)

Overall

Beta: 1.33
Market Cap (Mil.): $9,556.57
Shares Outstanding (Mil.): 72.74
Dividend: --
Yield (%): --

Financials

  ONXX.OQ Industry Sector
P/E (TTM): -- 47.13 37.76
EPS (TTM): -2.51 -- --
ROI: -11.63 -2.58 18.76
ROE: -17.03 -2.66 19.59
Search Stocks

Amgen profit tops Wall Street view; rebounds from first quarter

- Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.

30 Jul 2013

UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr

July 30 - Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.

30 Jul 2013

Amgen profit tops Wall Street view; rebounds from first quarter

- Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.

30 Jul 2013

Exclusive: Amgen lines up BofA, JPM, Barclays to finance Onyx deal -sources

NEW YORK - Amgen Inc, the world's largest biotechnology company, has lined up Bank of America Corp, JPMorgan Chase & Co and Barclays Plc to finance a potential deal for Onyx Pharmaceuticals Inc, according to three people familiar with the matter.

24 Jul 2013

Traders in Onyx in SEC insider case surface, claim innocence

NEW YORK - Two previously unnamed defendants have come forward in a U.S. Securities and Exchange Commission civil lawsuit over alleged insider trading in Onyx Pharmaceuticals Inc while the company was mulling a takeover bid, and said they did nothing wrong.

24 Jul 2013

UPDATE 2-Traders in Onyx in SEC insider case surface, claim innocence

* Two Dubai traders say call options purchases were lawful

24 Jul 2013

CORRECTED-UPDATE 1-Traders in Onyx in SEC insider case surface, claim innocence

(Corrects quotation in paragraph 10 to read "options trading" instead of "insider trading")

24 Jul 2013

CORRECTED-Traders in Onyx in SEC insider case surface, claim innocence

(Corrects quotation in paragraph 5 to read "options trading" instead of "insider trading")

24 Jul 2013

DEALTALK-Biotech takeover interest more fad than fashion

July 19 - Investors betting on a wave of big biotechnology deals following Amgen Inc's $10 billion bid for Onyx Pharmaceuticals Inc may well be disappointed.

19 Jul 2013

Exclusive: Pfizer not moving forward with Onyx bid: sources

NEW YORK - Pfizer Inc decided not to pursue a bid for Onyx Pharmaceuticals Inc this week, according to two people familiar with the matter, leaving Amgen Inc in the front position to buy the cancer drugmaker.

18 Jul 2013

Competitors

  Price Change
Takeda Pharmaceutical Company Limited (4502.T) ¥4,610 +30.00
Astellas Pharma Inc (4503.T) ¥5,310 -30.00
Pfizer Inc. (PFE.N) $29.11 -0.12
Novartis AG (NOVN.VX) CHF66.60 +0.35
Merck & Co., Inc. (MRK.N) $48.58 +0.41
Roche Holding Ltd. (ROG.VX) CHF228.00 -3.50
Bayer AG (BAYGn.DE) €89.43 +2.08
Bayer AG (BAYE.F) -- --
AstraZeneca plc (AZN.L) 3,334.00p -1.00
GlaxoSmithKline plc (GSK.L) 1,712.50p +28.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$58.00
Provider: Stock Traders Daily
$495.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks